Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Powell MA, Roed H, Willmott LJ, Cibula D, Black D, Valabrega G, Sharma S, Kommoss S, Landrum LM, Boere I, Mathews C, Sukhin V, Gold MA, Lundgren C, Gill SE, Gilbert L, Cass I, Edelson MI, Buscema J, Nevadunsky NS, Ring K, Pothuri B, Eshed HD, McCourt C, Coleman RL, Grimshaw M, Austin L, Zajac M, Slomovitz B, Nøttrup T

Open source

DOI: 10.1016/j.ygyno.2026.05.008
Published: 2026 Sep
Container: Gynecologic oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2026.05.008,
  title = {Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.},
  author = {Powell MA and Roed H and Willmott LJ and Cibula D and Black D and Valabrega G and Sharma S and Kommoss S and Landrum LM and Boere I and Mathews C and Sukhin V and Gold MA and Lundgren C and Gill SE and Gilbert L and Cass I and Edelson MI and Buscema J and Nevadunsky NS and Ring K and Pothuri B and Eshed HD and McCourt C and Coleman RL and Grimshaw M and Austin L and Zajac M and Slomovitz B and Nøttrup T},
  year = {2026},
  journal = {Gynecologic oncology},
  doi = {10.1016/j.ygyno.2026.05.008},
  url = {https://doi.org/10.1016/j.ygyno.2026.05.008}
}

RIS

TY  - JOUR
TI  - Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
AU  - Powell MA
AU  - Roed H
AU  - Willmott LJ
AU  - Cibula D
AU  - Black D
AU  - Valabrega G
AU  - Sharma S
AU  - Kommoss S
AU  - Landrum LM
AU  - Boere I
AU  - Mathews C
AU  - Sukhin V
AU  - Gold MA
AU  - Lundgren C
AU  - Gill SE
AU  - Gilbert L
AU  - Cass I
AU  - Edelson MI
AU  - Buscema J
AU  - Nevadunsky NS
AU  - Ring K
AU  - Pothuri B
AU  - Eshed HD
AU  - McCourt C
AU  - Coleman RL
AU  - Grimshaw M
AU  - Austin L
AU  - Zajac M
AU  - Slomovitz B
AU  - Nøttrup T
PY  - 2026
JO  - Gynecologic oncology
DO  - 10.1016/j.ygyno.2026.05.008
UR  - https://doi.org/10.1016/j.ygyno.2026.05.008
ER  -

APA

MA, P., H, R., LJ, W., D, C., D, B., G, V., S, S., S, K., LM, L., I, B., C, M., V, S., MA, G., C, L., SE, G., L, G., I, C., MI, E., J, B., NS, N., K, R., B, P., HD, E., C, M., RL, C., M, G., L, A., M, Z., B, S., & T, N. (2026). Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2026.05.008

Source records

pubmed · retrieved 2026-09-26T07:45:15.486Z
europe-pmc · retrieved 2026-09-26T07:45:15.497Z